Current concepts in Alzheimer's Disease: Molecules, models and translational perspectives

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Rutten, Bart P F ^a   Steinbusch, Harry W M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); GENETIC ASSOCIATION; NEUROFIBRILLARY TANGLE; PATHOPHYSIOLOGY; REVIEW; WORKSHOP;

ALZHEIMER DISEASE; ANIMALS; HUMANS;

EID: 84886937235     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-33     Document Type: Review

References (23)

1. Integrative genomics identifies APOE epsilon4 effectors in Alzheimer's disease. Rhinn H, Fujita R, Qiang L, Cheng R, Lee JH, Abeliovich A, Nature 2013 500 7460 45 50 10.1038/nature12415 23883936
2. The genetics of alzheimer disease. Tanzi RE, Cold Spring Harb Perspect Med 2012 2 10
3. Implication of common and disease specific variants in CLU, CR1, and PICALM. Ferrari R, Moreno JH, Minhajuddin AT, O'Bryant SE, Reisch JS, Barber RC, Momeni P, Neurobiol Aging 2012 33 8 1846 e1847 1818
4. Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased alzheimer risk. Bettens K, Brouwers N, Engelborghs S, Lambert JC, Rogaeva E, Vandenberghe R, Le Bastard N, Pasquier F, Vermeulen S, Van Dongen J, et al. Mol Neurodegener 2012 7 3 10.1186/1750-1326-7-3 22248099
5. TREM2 Variants in Alzheimer's disease. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. N Engl J Med 2013 368 2 117 127 10.1056/NEJMoa1211851 23150934
6. Gene-environment interaction research and transgenic mouse models of Alzheimer's disease. Chouliaras L, Sierksma AS, Kenis G, Prickaerts J, Lemmens MA, Brasnjevic I, van Donkelaar EL, Martinez-Martinez P, Losen M, De Baets MH, et al. Int J Alzheimers Dis 2010 2010
7. Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? Klein WL, J Alzheimers Dis 2013 33 Suppl 1 49 65 22785404
8. ADDLs and the signaling web that leads to Alzheimer's disease. Krafft GA, Klein WL, Neuropharmacology 2010 59 4-5 230 242 20650286
9. Blood-brain-barriers in aging and in Alzheimer's disease. Marques F, Sousa JC, Sousa N, Palha JA, Mol Neurodegener 2013 8 38 10.1186/1750-1326-8-38 24148264
10. Deciphering the mechanism underlying late-onset Alzheimer disease. Krstic D, Knuesel I, Nat Rev Neurol 2013 9 1 25 34 23183882
11. Inflammatory processes in Alzheimer's disease. Heneka MT, O'Banion MK, J Neuroimmunol 2007 184 1-2 69 91 17222916 (Pubitemid 46365992)
12. Modulation of iron metabolism in aging and in Alzheimer's disease: relevance of the choroid plexus. Mesquita SD, Ferreira AC, Sousa JC, Santos NC, Correia-Neves M, Sousa N, Palha JA, Marques F, Frontiers in cellular neuroscience 2012 6 25 22661928
13. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Chouliaras L, Rutten BP, Kenis G, Peerbooms O, Visser PJ, Verhey F, van Os J, Steinbusch HW, van den Hove DL, Prog Neurobiol 2010 90 4 498 510 10.1016/j.pneurobio.2010.01.002 20097254
14. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. Chouliaras L, Mastroeni D, Delvaux E, Grover A, Kenis G, Hof PR, Steinbusch HW, Coleman PD, Rutten BP, van den Hove DL, Neurobiol Aging 2013 34 9 2091 2099 10.1016/j.neurobiolaging.2013. 02.021 23582657
15. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Kapogiannis D, Mattson MP, Lancet Neurol 2011 10 2 187 198 10.1016/S1474-4422(10)70277-5 21147038
16. Cross-talk of membrane lipids and Alzheimer-related proteins. Walter J, van Echten-Deckert G, Mol Neurodegener 2013 8 34 10.1186/1750-1326-8-34 24148205
17. Alzheimer's disease: old problem, new views from transgenic and viral models. Jaworski T, Dewachter I, Seymour CM, Borghgraef P, Devijver H, Kugler S, Van Leuven F, Biochim Biophys Acta 2010 1802 10 808 818 10.1016/j.bbadis.2010. 03.005 20332023
18. Transgenic mouse models of alzheimer disease: developing a better model as a tool for therapeutic interventions. Kitazawa M, Medeiros R, Laferla FM, Curr Pharm Des 2012 18 8 1131 1147 10.2174/138161212799315786 22288400
19. Modeling Alzheimer's disease in transgenic rats. Carmo SD, Cuello AC, Mol Neurodegener 2013 8 37 10.1186/1750-1326-8-37 24161192
20. Drosophila melanogaster as a model organism for Alzheimer's disease. Pruessing K, Voigt A, Schulz JB, Mol Neurodegener 2013 8 35 10.1186/1750-1326-8- S1-P35
21. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, et al. Nature 2012 482 7384 216 220 22278060
22. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N, Hum Mol Genet 2011 20 23 4530 4539 10.1093/hmg/ddr394 21900357
23. Immunotherapy for Alzheimer's disease: hoops and hurdles. Lemere CA, Mol Neurodegener 2013 8 36 10.1186/1750-1326-8-36 24148220